Article

CVD risk stratification in COVID-19

CVD risk stratification in COVID-19

This globally renowned faculty has prepared an excellent agenda and will share their expertise and experience with us:

Prof. James Januzzi is a member of the Massachusetts General Hospital Cardiology Division and is on faculty at the Harvard Clinical Research Institute.  He shares with us insights on the global impact of the COVID-19 pandemic in diagnosis and management of CVD.

Dr. Raphael Twerenbold is an interventional cardiologist and senior physician at the Clinic for Cardiology at the University Hospital Basel. In this panel discussion, he talks about the background and mechanism of myocardial injury in COVID-19 patients.

Prof. Alexandre Mebazaa is Professor of Anaesthesiology and Critical Care Medicine at the Hôpital Lariboisière, University Paris 7, France: He sheds light on the incidence of acute cardiac dysfunction in the ICU during the Coronavirus pandemic.

Dr. Zhou Ning Associate Professor, Division of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. He provides us with learnings from China and from the clinical practice setting. 

The faculty used the opportunity to answer questions from you, our audience, such as: 

 

  • What could be the long term consequences of COVID-19; does it mean that recovered COVID-19 patients are at risk of multiple organ injury? 
  • What do you recommend as far as initial ventilator modes for patients with COVID-19, particularly the ones with cardiac dysfunction?
  • How did the cardiac biomarker data assist in clinical decision making for patients with COVID-19?
  • How long can one have the antibodies in the system and its association with the protection?
Key facts
  • Listen to a panel of global experts discussing COVID-19 pandemic and the way it affects patients with cardiovascular disease (CVD).
  • Additional topics such as the availability of antibodies in recovered patients, their association with protection from reinfection and the long term consequences of covid-19 were also discussed.
  • Furthermore, insights about the use of cardiac biomarkers to assist in clinical decision making in patients with covid-19 were also shared in this engaging panel discussion.